Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 15:211:49-56.
doi: 10.1016/j.amjcard.2023.10.071. Epub 2023 Nov 3.

Temporal Relation Between Myocardial Infarction and New-Onset Atrial Fibrillation: Results from a Nationwide Registry Study

Affiliations
Free article

Temporal Relation Between Myocardial Infarction and New-Onset Atrial Fibrillation: Results from a Nationwide Registry Study

Elin Karlsson et al. Am J Cardiol. .
Free article

Abstract

Myocardial infarction (MI) and atrial fibrillation (AF) are commonly seen in the same patient. In this study, we evaluated the temporal relations and prognosis of MI and AF. This is a substudy of the nationwide registry-based Finnish Anticoagulation in Atrial Fibrillation (FinACAF) study, comprising all Finnish patients with new-onset AF from 2010 to 2017. Patients with MI and AF were divided into groups depending on the temporal relation between the disease onsets: (1) MI before AF (MI<AF), (2) MI ± 30 days before or after AF (MI=AF), (3) MI after AF (MI>AF), and (4) no MI. The 1-year mortality in the groups were studied with the Cox proportional hazards model. Of the 153,207 patients with new-onset AF (mean age 72.7 years, 50.0% women), 16,265 (10.6%) were diagnosed with MI. Altogether, 8,889 (54.7%) of the patients with MI were in the MI<AF group, 4,278 (26.3%) were in the MI=AF group, and 3,098 (19.1%) were in the MI>AF group. Of all MIs, 42.2% were diagnosed within 1 year from new-onset AF. The MI>AF group had the worst survival, with an adjusted hazard ratio for death of 3.08 (confidence interval [CI] 2.89 to 3.27) compared with patients without MI. For the MI<AF and MI=AF groups, the hazard ratios were 1.34 (CI 1.27 to 1.41) and 1.69 (CI 1.59 to 1.81). In conclusion, the diagnoses of MI and AF accumulated close to one another, and the survival of patients with concomitant AF and MI varied, with the worst outcome found in patients with MI diagnosed after the new-onset AF.

Keywords: atrial fibrillation; mortality; myocardial infarction; real life; register study; survival.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Dr. Karlsson: research grants: AstraZeneca Heart Scholarship, granted by the Finnish Cardiac Society, Finska Läkaresällskapet. Dr. Kiviniemi: lecture fees: Bayer, Boehringer-Ingelheim, MSD, Astra Zeneca,St Jude Medical, and Bristol-Myers-Squibb-Pfizer. Research grants: the Horizon2020/EJCEL Moore for Medical, the Finnish Medical Foundation, the Finnish Foundation for Cardiovascular Research, Clinical Research Fund (EVO) of Turku University Hospital, Turku, Finland. Dr. Haukka: research grants: The Finnish Foundation for Cardiovascular Research, and EU Horizon 2020, EU FP7. Advisory board member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer; J.P.: consultant/speaker: Boehringer-Ingelheim, Bayer, BMS-Pfizer, Portola, Amgen, Herantis Pharma, Terve Media, Vital Signum, Abbott. Dr. Airaksinen: research grants: The Finnish Foundation for Cardiovascular Research; Speaker: Bayer, BMS-Pfizer-alliance and Boehringer-Ingelheim. Member in the advisory boards: Bayer, BMS-Pfizer-alliance and Astra Zeneca. Dr. Hartikainen: research grants: The Finnish Foundation for Cardiovascular Research, Advisory Board Member: BMS-Pfizer-alliance, Novo Nordisk, Amgen. Speaker: Cardiome, Bayer. Dr. Lehto: consultant: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, and MSD; Speaker: BMS-Pfizer-alliance, Bayer, Boehringer-Ingelheim, MSD, Terve Media, and Orion Pharma. Research grants: Aarne Koskelo Foundation, The Finnish Foundation for Cardiovascular Research, Helsinki and Uusimaa Hospital District research fund, and Boehringer-Ingelheim. Dr. Linna: speaker: BMS-Pfizer-alliance; P.M.: Consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer-Ingelheim, MSD Finland, Bayer. Dr. Mustonen: consultant: Roche, BMS-Pfizer-alliance, Novartis Finland, Boehringer-Ingelheim, MSD Finland. Dr. Putaala: research grants: Helsinki and Uusimaa Hospital District, Academy of Finland, The Finnish Foundation for Cardiovascular Research, Sigrid Juselius Foundation; Trial Country Leader: Bayer; Trial site-PI: Amgen, Bayer; Speaker: Bayer, Boehringer-Ingelheim, BMS-Pfizer, Abbott; Advisory Board: Portola, Novo Nordisk, Herantis Pharma; Visiting Editor: Terve Media; Stock ownership: Vital Signum. The remaining authors have no competing interest to declare.

Comment in

LinkOut - more resources